Vapotherm Inc. Announces $30 Million Financing Round - Gilde Healthcare

Vapotherm Inc. Announces $30 Million Financing Round

November 24, 2015

EXETER, NH,– Vapotherm, Inc., announced today it closed a $30 million equity financing last month. The first tranche of $15 million closed on October 30, 2015, and the second tranche is scheduled to close in September 2016. Arnerich Massena led the financing round, which included one new investor, Perceptive Advisors, along with current investors Gilde Healthcare Partners, Morgenthaler Ventures, QuestMark Partners, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.

“We are delighted by our investors’ continued support of Vapotherm. Their support helps us provide High Flow Therapy, our unique respiratory solution to improve clinical and economic outcomes for customers and the patients they serve,” said Joe Army, President and CEO of Vapotherm.

Tony Arnerich, CEO of Arnerich Massena, commented “We are enthusiastic about continuing to support Vapotherm. This new capital will help the company continue the expansion of the U.S. field organization, develop new products and expand in select International markets.”

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 700,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vtherm.com.

Contact: John Landry, VP & CFO
T: (603) 658-0011

More news

Gilde Healthcare acquires MEG, a group of specialized providers of medical aids, from Harald Quandt Industriebeteiligungen (“HQIB”)

Gilde Healthcare’s private equity fund today announced the acquisition of MEG Medical Equipment GmbH (“MEG”), a provider of high-quality medical aids for treatment and prevention of decubitus and other skin damages resulting from extended immobility,...
November 14, 2025

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025